EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GD2-Targeted Minibody–Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model

Daniel V Kalinovsky iD, Matvey M Titov, Irina V Kholodenko iD, Alexey V Kibardin, Elena V Svirshchevskaya, Sergey M Deyev iD, Roman V Kholodenko iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27041974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Daniel V Kalinovsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia. Hauptthemen laut MEDLINE: Gangliosides, Immunoconjugates, Immunoglobulin G. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the clinical success of antibody–drug conjugates (ADCs), their efficacy in solid tumors remains constrained by limited tumor penetration of the IgG format. Smaller antibody fragment–drug conjugates (FDCs) present a compelling alternative, potentially offering superior intratumoral distribution and a wider therapeutic window driven by rapid systemic clearance. This study compares therapeutic activity of ganglioside GD2-specific minibody–drug conjugates against full-length ch14.18 antibody–drug conjugates, and biodistribution of the respective minibody (scFv-CH3 homodimer) and IgG formats in the GD2-positive B78-D14 melanoma syngeneic mouse model. We conjugated the minibody and antibody with MMAE or MMAF via a cathepsin-cleavable linker, generating FDCs with drug–antibody ratio (DAR) of 2 and ADCs with DAR of 2 or 4. The biodistribution analysis showed no significant difference in tumor uptake for both formats early in the analysis (2–4 h) and a higher tumor uptake for the IgG at 24 h post-injection. However, the minibody achieved a superior tumor-to-blood ratio (TBR) at all timepoints, reaching a TBR > 1 compared to ~0.2 for the antibody by 24 h. In vitro studies demonstrated higher cytotoxicity for the ADCs regardless of drug load (DAR 2 or 4) compared to the FDCs, although the difference between conjugates with equal DAR was modest in B78-D14 cells. Critically, superior in vitro ADC potency did not translate in vivo. Minibody–MMAF and minibody–MMAE achieved 74% and 55% tumor growth inhibition, respectively, by the study endpoint—demonstrating comparable efficacy to ADCs with twice the drug load when administered to mice at equimass dosing. Stron/g in vivo efficacy of anti-GD2 FDCs, combined with the superior TBR for the minibody format, underscores the potential of minibody–drug conjugates for treating GD2-positive tumors, particularly when ADC-associated toxicity precludes high-dose regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GangliosidesImmunoconjugatesImmunoglobulin GAnimalsMiceTissue DistributionCell Line, TumorFemaleDisease Models, AnimalHumans

Stichwörter der Autor:innen

GD2-positive tumorsantibody fragment-drug conjugatesantibody fragmentsantibody-drug conjugatescancerganglioside GD2immunotherapymelanomaminibodiesneuroblastoma

Substanzen

GangliosidesImmunoconjugatesImmunoglobulin Gganglioside, GD2

Autor:innen und Institutionen

  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
  • Orekhovich Institute of Biomedical Chemistry, Moscow 119121, Russia.
  • D. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117997, Russia.
  • Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
  • Federal Center for Biotechnology and Medicine Advancement, National Research Ogarev Mordovia State University, Saransk 430005, Russia.

ORCID-Profile: Daniel V Kalinovsky, Irina V Kholodenko, Sergey M Deyev, Roman V Kholodenko

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Kalinovsky, D. V., Titov, M. M., Kholodenko, I. V., Kibardin, A. V., Svirshchevskaya, E. V., Deyev, S. M., & Kholodenko, R. V. (2026). GD2-Targeted Minibody–Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041974

Vancouver

Kalinovsky DV, Titov MM, Kholodenko IV, Kibardin AV, Svirshchevskaya EV, Deyev SM, et al. GD2-Targeted Minibody–Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041974

BibTeX
@article{Kalinovsky2026,
  author = {Kalinovsky, Daniel V and Titov, Matvey M and Kholodenko, Irina V and Kibardin, Alexey V and Svirshchevskaya, Elena V and Deyev, Sergey M and Kholodenko, Roman V},
  title = {GD2-Targeted Minibody–Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27041974}
}
Kostenlos starten →